Brazilian authorities approved the world’s first single-dose dengue vaccine on Wednesday, marking what they called a “historic” step as dengue cases surge worldwide due to rising temperatures. Dengue, known for its intense flu-like symptoms, severe fatigue, and body aches, reached record global levels in 2024. Researchers have linked its rapid spread to climate change.
Regulatory Nod for Butantan-DV
Brazil’s health regulatory agency, ANVISA, authorized the Butantan-DV vaccine for individuals aged 12 to 59. Developed by the Butantan Institute in São Paulo, the vaccine promises a simpler and faster immunization strategy. Until now, the only globally available dengue vaccine has been TAK-003, which requires two doses given three months apart, according to the World Health Organization (WHO).
Eight Years of Research Lead to Breakthrough
After eight years of nationwide clinical trials, the single-dose vaccine emerged as a major scientific achievement. Esper Kallas, director of the Butantan Institute, stressed its significance at a press conference in São Paulo. He noted that a disease troubling Brazil for decades can now be countered with “a very powerful weapon.”
Strong Efficacy Against Severe Disease
As reported by medicalxpress, clinical trials involving more than 16,000 volunteers showed that Butantan-DV delivered 91.6% efficacy against severe dengue. Often called “breakbone fever” due to its painful symptoms, dengue can escalate into hemorrhagic fever and, in some cases, cause death.
Global Spread Intensifies With Climate Change
Moreover, infected Aedes mosquitoes have expanded into new geographic areas, triggering cases in regions such as Europe and parts of the United States that previously saw few or no infections. In 2024, the WHO recorded more than 14.6 million dengue cases and nearly 12,000 deaths—half of them in Brazil. A Stanford University study estimated that global warming contributed to 19% of dengue infections that year.
Brazil Plans Large-Scale Vaccine Supply
Looking ahead, Brazil reached an agreement with Chinese company WuXi Biologics to supply about 30 million doses of the new vaccine in the second half of 2026, Health Minister Alexandre Padilha announced.